<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Endocr Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Endocr Soc</journal-id><journal-id journal-id-type="publisher-id">JS</journal-id><journal-id journal-id-type="pmc">JS</journal-id><journal-title-group><journal-title>Journal of the Endocrine Society</journal-title></journal-title-group><issn pub-type="epub">2472-1972</issn><publisher><publisher-name>Endocrine Society</publisher-name><publisher-loc>Washington, DC</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29264502</article-id><article-id pub-id-type="pmc">5686597</article-id><article-id pub-id-type="publisher-id">JS_201700037</article-id><article-id pub-id-type="doi">10.1210/js.2017-00037</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research Articles</subject><subj-group><subject>Thyroid</subject></subj-group></subj-group></article-categories><title-group><article-title>Effect of Vitamin D on Thyroid Autoimmunity: A Randomized, Double-Blind, Controlled Trial Among Ethnic Minorities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Knutsen</surname><given-names>Kirsten V.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Madar</surname><given-names>Ahmed A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brekke</surname><given-names>Mette</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meyer</surname><given-names>Haakon E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eggemoen</surname><given-names>&#x000c5;se Ruth</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mdala</surname><given-names>Ibrahimu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lagerl&#x000f8;v</surname><given-names>Per</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><aff id="aff1"><label>1</label>Department of General Practice, Institute of Health and Society, University of Oslo, 0318 Oslo, Norway;</aff><aff id="aff2"><label>2</label>Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, 0318 Oslo, Norway</aff><aff id="aff3"><label>3</label>Division of Epidemiology, Norwegian Institute of Public Health, 0403 Oslo, Norway</aff></contrib-group><author-notes><corresp id="cor1">Address all correspondence to: Kirsten V. Knutsen, PhD, MD, Department of General Practice, Institute of Health and Society, University of Oslo, Norway. E-mail: <email>k.i.v.knutsen@medisin.uio.no</email>.</corresp></author-notes><pub-date pub-type="collection"><day>01</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>11</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>4</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>1</volume><issue>5</issue><fpage>470</fpage><lpage>479</lpage><history><date date-type="received"><day>04</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>03</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2017 Endocrine Society</copyright-statement><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p></license></permissions><self-uri xlink:title="pdf" content-type="pdf" xlink:href="js-01-470.pdf"/><abstract><sec id="s1"><title>Context:</title><p>Autoimmune thyroid disorders have been linked to vitamin D deficiency, but an effect of vitamin D supplementation is not established.</p></sec><sec id="s2"><title>Objective:</title><p>Our objective was to test whether vitamin D compared with placebo could reduce thyroid autoantibodies.</p></sec><sec id="s3"><title>Design:</title><p>Predefined additional analyses from a randomized, double-blind, placebo-controlled trial.</p></sec><sec id="s4"><title>Setting:</title><p>The study was conducted in different community centers in Oslo, Norway.</p></sec><sec id="s5"><title>Participants:</title><p>A total of 251 presumed healthy men and women, aged 18 to 50 years, with backgrounds from South Asia, the Middle East, and Africa were included.</p></sec><sec id="s6"><title>Intervention:</title><p>Daily supplementation with 25 &#x000b5;g (1000 IU) vitamin D<sub>3</sub>, 10 &#x000b5;g (400 IU) vitamin D<sub>3</sub>, or placebo for 16 weeks.</p></sec><sec id="s7"><title>Outcome Measure:</title><p>Difference in preintervention and postintervention antithyroid peroxidase antibody (TPOAb) levels. Additional outcomes were differences in thyroid-stimulating hormone (TSH) and free fraction of thyroxine (fT4).</p></sec><sec id="s8"><title>Results:</title><p>There were no differences in change after 16 weeks on TPOAb (27 kU/L; 95% CI, &#x02212;17 to 72; <italic>P</italic> = 0.23), TSH (&#x02212;0.10 mU/L; 95% CI, &#x02212;0.54 to 0.34; <italic>P</italic> = 0.65), or fT4 (0.09 pmol/L; 95% CI, &#x02212;0.37 to 0.55; <italic>P</italic> = 0.70) between those receiving vitamin D supplementation or placebo. Mean serum 25(OH)D<sub>3</sub> increased from 26 to 49 nmol/L in the combined supplementation group, but there was no change in the placebo group.</p></sec><sec id="s9"><title>Conclusion:</title><p>Vitamin D<sub>3</sub> supplementation, 25 &#x000b5;g or 10 &#x000b5;g, for 16 weeks compared with placebo did not affect TPOAb level in this randomized, double-blind study among participants with backgrounds from South Asia, the Middle East, and Africa who had low vitamin D levels at baseline.</p></sec></abstract><abstract abstract-type="teaser"><p>Vitamin D<sub>3</sub> supplementation for 16 weeks compared with placebo did not change the thyroid autoimmunity or thyroid status in this randomized, double-blind, placebo-controlled study among ethnic minorities.</p></abstract><kwd-group><kwd>vitamin D</kwd><kwd>autoimmune thyroid disease</kwd><kwd>thyroid hormone</kwd><kwd>randomized controlled trial</kwd><kwd>ethnicity</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="26"/><page-count count="10"/></counts></article-meta></front><body><p>Vitamin D deficiency is widespread, with a high prevalence among ethnic minority populations living in Western countries [<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr"/>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. In Norway vitamin D deficiency is frequently found among ethnic minorities with backgrounds from the Middle East, Asia, and Africa [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. The main effect of vitamin D is to regulate calcium&#x02013;phosphate metabolism. However, in recent years numerous studies have indicated that vitamin D may have several other functions, including a possible role in the immune system [<xref rid="B6" ref-type="bibr">6</xref>]. <italic>In vivo</italic> data have suggested beneficial effects of vitamin D on immune function, particularly in the context of autoimmunity. Exposure to vitamin D may lead to a shift from a proinflammatory to a more tolerogenic immune status in animals and humans [<xref rid="B7" ref-type="bibr">7</xref>]. Low levels of vitamin D may contribute to the development of autoimmune diseases, including predisposition to autoimmune disorders [<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr"/>&#x02013;<xref rid="B10" ref-type="bibr">10</xref>].</p><p>The thyroid gland is important in regulating the body&#x02019;s metabolism. The autoimmune thyroid diseases (AITDs) are common worldwide, and &#x02264;10% of the adult population is affected. The prevalence increases with age, and more women than men are affected [<xref rid="B11" ref-type="bibr">11</xref>]. Multiple environmental factors and genes are involved in the development of AITDs [<xref rid="B12" ref-type="bibr">12</xref><xref rid="B13" ref-type="bibr"/>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>]. The AITD may have a gradual, slow or fast onset and may debut after pregnancy, presenting with hypothyroid or hyperthyroid symptoms. Despite elevated levels of antithyroid peroxidase antibody (TPOAb), a marker of autoimmune-mediated destruction of the thyroid tissue, the free fraction of thyroxine (fT4) may be within normal range because of an increased level of thyroid-stimulating hormone (TSH), and the patient can remain without symptoms for a period, being subclinically hypothyroid [<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Some studies have reported an association between low vitamin D status and AITD, and Kivity <italic>et al.</italic> reported an association between vitamin D deficiency and thyroid antibodies in 2011 [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B16" ref-type="bibr">16</xref>]. A meta-analysis of 20 case&#x02013;control studies found that patients with AITD were more likely to be vitamin D deficient than controls [<xref rid="B6" ref-type="bibr">6</xref>]. There are some indications that vitamin D supplementation suppresses the autoimmune reaction and thereby reduces the levels of thyroid autoantibodies [<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>]. However, this effect is still controversial, and other authors have not found vitamin D deficiency to increase the risk of AITD or to be associated with early stages of AITD [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>].</p><p>We present here results for the predefined secondary outcomes of our previously reported randomized, double-blind, placebo-controlled trial on the effect of vitamin D supplementation on muscle strength and power in a young adult ethnic minority population living in Norway [<xref rid="B21" ref-type="bibr">21</xref>]. Our hypothesis was that 16 weeks of daily vitamin D<sub>3</sub> (25 &#x003bc;g/d or 10 &#x003bc;g/d) would reduce the thyroid autoantibodies compared with placebo in this population with unknown thyroid autoantibody status and with presumed high prevalence of low vitamin D levels.</p><sec id="s10"><title>1. Materials and Methods</title><sec id="s11"><title>A. Study Design, Setting, and Participants</title><p>This double-blinded, block randomized, placebo-controlled, parallel-group trial was conducted in Oslo, Norway (at latitude 60&#x000b0;N) between January and June 2011. The participants came from an assumed healthy population, men and women, aged 18 to 50 years who were born in or had parents born in the Middle East, Africa, or South Asia. They were recruited through local immigrant organizations, and the study was conducted in these activity centers. Details of the study methods have been described elsewhere (ClinicalTrials.gov identifier NCT01263288) [<xref rid="B21" ref-type="bibr">21</xref>]. The exclusion criteria were regular use of vitamin D&#x02013;containing supplements, ongoing treatment of vitamin D deficiency, use of strong pain killers or medication interfering with vitamin D metabolism (<italic>e.g.,</italic> thiazides, antiepileptic drugs, prednisolone, or hormone replacement therapy), pregnancy, breastfeeding, kidney disease, cancer, tuberculosis, sarcoidosis, osteoporosis, or a recent fracture. None of the participants reported use of thyroid hormone supplements.</p></sec><sec id="s12"><title>B. Intervention, Randomization, and Blinding</title><p>Participants who provided consent to participate and fulfilled the eligibility criteria were randomly assigned to one of three equally sized intervention groups given 25 &#x000b5;g of vitamin D<sub>3</sub>, 10 &#x000b5;g of vitamin D<sub>3</sub>, or placebo. We included one intervention group with 10 &#x000b5;g of vitamin D<sub>3</sub>/day because this was the recommended daily intake according to official Norwegian guidelines when the study was performed. The other intervention arm had 25 &#x000b5;g of vitamin D<sub>3</sub>/day, a dietary supplement dosage approved by authorities in Europe (Denmark and the United Kingdom). The tablets were identical in color, size, taste, and packaging. Group allocations were unknown to participants, research staff, investigators, and data collectors. Randomly varying the block size between three and six (computer-generated) ensured a good balance of gender and different ethnicity in each group. Each participant received a box with 120 tablets (112 tablets correspond to 16 weeks of use). Participants were advised to take two tablets the next day if they had forgotten to take a tablet the previous day and to maintain their usual dietary pattern. To maximize adherence, the participants received brief reminders via mobile phone text messages twice a week during the 16-week trial. Compliance with the supplementation was confirmed by counting the number of tablets in the returned boxes at follow-up.</p><p>The number of participants in this study was based on power calculations to investigate the effect of vitamin D supplementation on muscle strength and power (Clinical Trials.gov identifier NCT01263288), and these primary end points have been previously reported [<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec id="s13"><title>C. Main outcome Variables</title><p>The study outcomes were the predefined difference in change during the intervention (T2 &#x02212; T1) between the combined intervention groups (25 &#x000b5;g and 10 &#x000b5;g) of vitamin D<sub>3</sub>/day and placebo, in the following thyroid parameters: TPOAb, TSH, and fT4.</p></sec><sec id="s14"><title>D. Blood Sampling and Laboratory Assays</title><p>At baseline and at follow-up examination after 16 weeks, blood samples (nonfasting) were collected from the participants. Blood for analyses of serum and plasma was collected and handled in separate tubes and stored at &#x02212;20&#x000b0;C the same day and within 1 to 2 weeks frozen at &#x02212;80&#x000b0;C storage. The samples, from baseline and follow-up, were analyzed in one batch at F&#x000fc;rst Medical Laboratory, Oslo, Norway (<ext-link ext-link-type="uri" xlink:href="http://www.furst.no/">http://www.furst.no/</ext-link>), accredited by the International Organization for Standardization and part of the Vitamin D Quality Assessment Scheme. Serum 25-hydroxyvitamin D [25(OH)D] was measured with high-pressure liquid chromatography tandem mass spectrometry, able to measure both 25(OH)D<sub>3</sub> and 25(OH)D<sub>2</sub>. Serum 25(OH)D<sub>2</sub> was negligible in this population, and 25(OH)D<sub>3</sub> was used in the statistical analysis. Serum TPOAb, serum TSH, serum fT4, and plasma parathyroid hormone (PTH) were determined by chemiluminescence method (ADVIA Centaur XP, Siemens) with an interassay coefficient of variation (CV), respectively 6.1%, 4.6%, 6.6%, and 8.2%. The C-reactive protein (CRP) (CV 2.2%), including high-sensitivity CRP for CRP values &#x0003c;11 mg/L, was measured with a latex-reinforced immunoturbidimetric method (ADVIA 2400, Siemens) [<xref rid="B22" ref-type="bibr">22</xref>]. The liver enzymes serum aspartate aminotransferase and serum alanine aminotransferase were determined by NADH with pyridoxal phosphate (ADVIA 2400, Siemens) and interassay CV to be 3.3% and 3.7%, respectively. Serum albumin (CV 2.1%) was measured with bromocresol green (ADVIA 2400, Siemens).</p></sec><sec id="s15"><title>E. Statistical Analyses</title><p>The generalized estimating equation (GEE) regression method was applied in the analyses of both continuous and binary responses of observations in participants and can compare all participants at inclusion with all participants at follow-up. The outcome variables at the end of the trial were unadjusted and adjusted for gender, age, and baseline values of vitamin D<sub>3</sub>. Because thyroid function was not the primary endpoint of the trial, the Benjamini&#x02013;Hochberg procedure was used to control for multiple testing. Correlations were measured with parametric (Pearson) or nonparametric (Spearman) methods. Measured levels of TPOAb were replaced with 24 kU/L if measured as &#x0003c;25 kU/L and with 1301 kU/L if measured as &#x0003e;1300 kU/L. Statistical analyses of the data were performed with SPSS (IBM SPSS Statistic, version 21).</p></sec><sec id="s16"><title>F. Registration and Ethics</title><p>The Norwegian Medicine Agency authorized this study as a clinical trial. The study is registered at EudraCT (2010-021114-36). Tablets were manufactured by BioPlus Life Sciences Pvt Ltd, certificated for good manufacturing practice by The Danish Medicines Agency, and the ingredients met the requirements of British Pharmacop&#x000e9;. The study was approved by the Regional Committee for Medical and Health Research Ethics (study code 2010/1982), and all participants gave written informed consent. The participants were advised to contact the study staff by telephone if they had any questions related to the study. The trial was conducted in accordance with national laws and according to the principles of the Declaration of Helsinki (ClinicalTrials.gov identifier NCT01263288).</p></sec></sec><sec id="s17"><title>2. Results</title><sec id="s18"><title>A. Study Sample</title><p>Of 301 people who volunteered for the study, 251 met the inclusion criteria and were randomly assigned to vitamin D<sub>3</sub> 25 &#x000b5;g/d, vitamin D<sub>3</sub> 10 &#x000b5;g/d, or placebo. More women (73%) than men were included. After 16 weeks, 215 (86%) attended the follow-up visit (<xref ref-type="fig" rid="F1">Fig. 1</xref>), and nonfasting blood was collected from 214. At the end of the study 1 participant reported use of thyrostatic medication at inclusion and during the study, and this participant was excluded, resulting in a total of 250 participants at baseline and 213 at follow-up in this analysis. Eighty percent of the participants had consumed &#x0003e;80% of the study tablets, and 69% consumed &#x0003e;90% of the study tablets.</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Flow diagram. Effect of vitamin D<sub>3</sub> supplementation on thyroid parameters among ethnic minorities in Norway. A randomized, double-blinded, placebo-controlled study.</p></caption><graphic xlink:href="js-01-470-f1"/></fig></sec><sec id="s19"><title>B. Baseline Characteristics</title><p>Median concentration for TPOAb was 49 [interquartile range (IQR) 42 to 59] kU/L (range &#x0003c;25 to &#x0003e;1300 kU/L); 10% (25/250) had levels &#x02265;100 kU/L, 49% (123/250) had levels &#x02265;50 kU/L, and 86% (216/250) had levels &#x02265;35 kU/L. Mean concentration of fT4 was 16.2 (SD 1.7) pmol/L, all within the reference range (9&#x02013;22 pmol/L) (<xref ref-type="table" rid="T1">Table 1</xref>). Mean concentration of TSH was 1.9 (SD 1.3) mU/L; 63% (158/250) had levels &#x0003c;2.0 mU/L, and 33% (83/250) had levels between 2.0 and 4.0 mU/L. Seven out of 250 participants (2.8%) had TSH &#x0003e;4.0 mU/L. Five of these participants had subclinical hypothyroidism with slightly elevated TSH (4.3 to 9.1 mU/L) and TPOAb between 52 and &#x0003e;1300 kU/L. The remaining two participants had higher TSH levels (10.0 and 11.0 mU/L) and TPOAb (50 and 746 kU/L). Mean concentration of 25(OH)D<sub>3</sub> was 26 (SD 15) nmol/L (range 5 to 87 nmol/L), and only 8% had serum concentration &#x02265;50 nmol/L.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p><bold>Baseline Characteristics of the Three Allocation Groups Among 250 Participants in the Study of the Effect of Vitamin D<sub>3</sub> on Thyroid Parameters. Number (%), Mean (SD), or Median With IQR</bold></p></caption><table frame="above" rules="groups"><col width="29.4" span="1"/><col width="18.28" span="1"/><col width="18.2" span="1"/><col width="18.2" span="1"/><col width="15.92" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Vitamin D<sub>3</sub> 25 &#x000b5;g</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Vitamin D<sub>3</sub> 10 &#x000b5;g</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Placebo</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">All<xref ref-type="table-fn" rid="t1n1"><italic><sup>a</sup></italic></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Characteristic</td><td valign="top" align="center" rowspan="1" colspan="1">n = 83</td><td valign="top" align="center" rowspan="1" colspan="1">n = 85</td><td valign="top" align="center" rowspan="1" colspan="1">n = 82</td><td valign="top" align="center" rowspan="1" colspan="1">n = 250</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Women</td><td valign="top" align="center" rowspan="1" colspan="1">57 (69%)</td><td valign="top" align="center" rowspan="1" colspan="1">61 (72%)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (77%)</td><td valign="top" align="center" rowspan="1" colspan="1">181 (72%)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age, y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="center" rowspan="1" colspan="1">35 (7.5)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (7.6)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (7.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="center" rowspan="1" colspan="1">40 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (6.6)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (7.8)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (7.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnic origin<xref ref-type="table-fn" rid="t1n2"><italic><sup>b</sup></italic></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;South Asia</td><td valign="top" align="center" rowspan="1" colspan="1">31 (37%)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (36%)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (40%)</td><td valign="top" align="center" rowspan="1" colspan="1">95 (38%)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Middle East and North Africa</td><td valign="top" align="center" rowspan="1" colspan="1">15 (18%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (11%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (15%)</td><td valign="top" align="center" rowspan="1" colspan="1">36 (14%)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Sub-Saharan Africa</td><td valign="top" align="center" rowspan="1" colspan="1">37 (45%)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (53%)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (45%)</td><td valign="top" align="center" rowspan="1" colspan="1">119 (48%)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">TPOAb,<xref ref-type="table-fn" rid="t1n3"><italic><sup>c</sup></italic></xref> kU/L</td><td valign="top" align="center" rowspan="1" colspan="1">50 (43&#x02013;60)</td><td valign="top" align="center" rowspan="1" colspan="1">48 (39&#x02013;58)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (43&#x02013;59)</td><td valign="top" align="center" rowspan="1" colspan="1">117 (264)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="center" rowspan="1" colspan="1">49 (41&#x02013;60)</td><td valign="top" align="center" rowspan="1" colspan="1">48 (38&#x02013;56)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (39&#x02013;59)</td><td valign="top" align="center" rowspan="1" colspan="1">103 (231)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="center" rowspan="1" colspan="1">54 (47&#x02013;60)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (40&#x02013;61)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (45&#x02013;60)</td><td valign="top" align="center" rowspan="1" colspan="1">152 (334)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">TSH, mU/L</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1&#x02013;2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.6 (1.1&#x02013;2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.0&#x02013;2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1&#x02013;2.5)</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (1.2&#x02013;2.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1&#x02013;2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.2&#x02013;2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1&#x02013;2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.9&#x02013;2.4)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">fT4, pmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">16.4 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">16.2 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">15.9 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16.2 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="center" rowspan="1" colspan="1">16.1 (1.7)</td><td valign="top" align="center" rowspan="1" colspan="1">16.1 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">15.8 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16.0 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="center" rowspan="1" colspan="1">17.3 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">16.5 (1.7)</td><td valign="top" align="center" rowspan="1" colspan="1">16.3 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16.8 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">25(OH)D<sub>3</sub>, nmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">27 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (15)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Women</td><td valign="top" align="center" rowspan="1" colspan="1">27 (17)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (15)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Men</td><td valign="top" align="center" rowspan="1" colspan="1">28 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">29 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (15)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">P-PTH,<xref ref-type="table-fn" rid="t1n4"><italic><sup>d</sup></italic></xref> pmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">7.4 (5.2&#x02013;9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">6.4 (5.2&#x02013;8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">7.4 (5.0&#x02013;9.8)</td><td valign="top" align="center" rowspan="1" colspan="1">7.6 (3.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Calcium, mmol/L</td><td valign="top" align="center" rowspan="1" colspan="1">2.36 (0.09)</td><td valign="top" align="center" rowspan="1" colspan="1">2.36 (0.08)</td><td valign="top" align="center" rowspan="1" colspan="1">2.36 (0.10)</td><td valign="top" align="center" rowspan="1" colspan="1">2.36 (0.09)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CRP, mg/L</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (0.8&#x02013;6.0)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (0.9&#x02013;4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 (0.8&#x02013;4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">4.4 (6.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Serum aspartate aminotransferase, U/L</td><td valign="top" align="center" rowspan="1" colspan="1">20 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Serum alanine aminotransferase, U/L</td><td valign="top" align="center" rowspan="1" colspan="1">23 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (13)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (14)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Albumin, g/L</td><td valign="top" align="center" rowspan="1" colspan="1">44 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (2)</td></tr></tbody></table><table-wrap-foot><fn id="t1n1"><p><sup><italic>a</italic></sup>All, characteristics with only number (%) or mean (SD), not with median (IQR).</p></fn><fn id="t1n2"><p><sup><italic>b</italic></sup>Ninety-five participants came from South Asia (primarily Sri Lanka, Pakistan, and Afghanistan), 36 participants from the Middle East and North Africa (primarily Morocco, Iraq, and Syria), and 119 participants from sub-Saharan Africa (primarily Somalia and Ethiopia). In this study all the participants had parents from the same geographic area.</p></fn><fn id="t1n3"><p><sup><italic>c</italic></sup>TPOAb &#x0003c;25 kU/L given value 24 (n = 2) and &#x0003e;1300 kU/L given value 1301 (n = 11).</p></fn><fn fn-type="other"><p>Reference range: TPOAb &#x0003c;100 kU/L, serum TSH, (0.20&#x02013;4.0 mU/L), serum fT4 (9&#x02013;22 pmol/L), serum albumin (36&#x02013;48 g/L).</p></fn><fn id="t1n4"><p><sup><italic>d</italic></sup>Missing 5 values of PTH at baseline.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s20"><title>C. Effect of Supplementation on Vitamin D Status</title><p>As reported previously, serum 25(OH)D<sub>3</sub> increased after 16 weeks of supplementation by 25 (SD 22) nmol/L, from 27 to 52 nmol/L, in the group receiving 25 &#x000b5;g vitamin D<sub>3</sub> (<italic>P</italic> &#x0003c; 0.001), and increased by 16 (SD 20) nmol/L, from 27 to 43 nmol/L, in the group receiving 10 &#x000b5;g vitamin D<sub>3</sub> (<italic>P</italic> &#x0003c; 0.001) [<xref rid="B21" ref-type="bibr">21</xref>]. There was no significant change in 25(OH)D<sub>3</sub> in the placebo group, measured to 27 (SD 15) nmol/L at baseline and 25 (SD 12) nmol/L after 16 weeks.</p></sec><sec id="s21"><title>D. Effect of Supplementation on End Point Measures</title><p>Sixteen weeks of supplementation with vitamin D<sub>3</sub> (combined 25 &#x000b5;g/d or 10 &#x000b5;g/d) compared with placebo had no significant effect on TPOAb (<italic>P</italic> = 0.23), TSH (<italic>P</italic> = 0.65), or fT4 (<italic>P</italic> = 0.70) (<xref ref-type="table" rid="T2">Table 2</xref>). Analyses of each supplementation group compared with placebo did not show any significant effect on TPOAb, TSH, or fT4 (<xref ref-type="table" rid="T3">Table 3</xref>). The effect was not changed by adjusting for age, gender, and baseline level of vitamin D<sub>3</sub> (<xref ref-type="table" rid="T2">Tables 2</xref> and <xref ref-type="table" rid="T3">3</xref>). The total number of participants with TPOAb levels &#x0003c;50 kU/L decreased from 51% at baseline to 36% after 16 weeks, odds ratio (OR) = 0.54 (95% CI, 0.39 to 0.75), <italic>P</italic>
<italic>&#x0003c;</italic> 0.001, but there were no differences between those given supplementation and placebo (<italic>P</italic> = 0.58). The effect of the end point measures was not changed when we excluded seven participants with elevated TSH &#x0003e;4.0 mU/L at baseline. A sensitivity analysis of only participants with TPOAb &#x0003c;100 kU/L at baseline (n = 225) gave <italic>&#x003b2;</italic>= 1.1 (95% CI, &#x02212;3.1 to 5.3), <italic>P</italic> = 0.60. A separate analysis comparing the change of 25(OH)D<sub>3</sub> and the change in TPOAb, independent of group allocation, showed no significant correlation.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p><bold>Effect of Vitamin D<sub>3</sub> Supplementation (25 &#x000b5;g and 10 &#x000b5;g Combined) on Thyroid and Related Parameters at the End of Intervention Compared With Placebo</bold></p></caption><table frame="above" rules="groups"><col width="19.06" span="1"/><col width="11.35" span="1"/><col width="12.48" span="1"/><col width="20.88" span="1"/><col width="6.04" span="1"/><col width="23.38" span="1"/><col width="6.81" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Baseline<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">After 16 Wk<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Effect (95% CI) of Vitamin D<sub>3</sub> Compared With Placebo<xref ref-type="table-fn" rid="t2n1"><italic><sup>a</sup></italic></xref><hr/></th><th valign="top" align="center" scope="colgroup" rowspan="1" colspan="1"><italic>P</italic></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Adjusted Effect (95% CI) of Vitamin D<sub>3</sub> Compared With Placebo<xref ref-type="table-fn" rid="t2n2"><italic><sup>b</sup></italic></xref><hr/></th><th valign="top" align="center" scope="colgroup" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2n2"><italic><sup>b</sup></italic></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Participants, number</td><td valign="top" align="center" rowspan="1" colspan="1">250</td><td valign="top" align="center" rowspan="1" colspan="1">213</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">168</td><td valign="top" align="center" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">n (%)</td><td valign="top" align="center" rowspan="1" colspan="1">OR</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">OR</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb &#x0003c;100 kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">153 (91%)</td><td valign="top" align="center" rowspan="1" colspan="1">128 (90%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.82 (0.55 to 1.23)</td><td valign="top" align="center" rowspan="1" colspan="1">0.34</td><td valign="top" align="center" rowspan="1" colspan="1">0.81 (0.54 to 1.23)</td><td valign="top" align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">72 (88%)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (89%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb &#x0003c;50 kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">86 (51%)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (35%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.82 (0.40 to 1.67)</td><td valign="top" align="center" rowspan="1" colspan="1">0.58</td><td valign="top" align="center" rowspan="1" colspan="1">0.80 (0.38 to 1.66)</td><td valign="top" align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">41 (50%)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (38%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">B</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">B</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb, kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">111 (255)</td><td valign="top" align="center" rowspan="1" colspan="1">115 (254)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (&#x02212;17 to 72)</td><td valign="top" align="center" rowspan="1" colspan="1">0.23</td><td valign="top" align="center" rowspan="1" colspan="1">28 (&#x02212;17 to 72)</td><td valign="top" align="center" rowspan="1" colspan="1">0.23</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">128 (282)</td><td valign="top" align="center" rowspan="1" colspan="1">105 (217)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TSH, mU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (1.2)</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.10 (&#x02212;0.54 to 0.34)</td><td valign="top" align="center" rowspan="1" colspan="1">0.65</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.11 (&#x02212;0.54 to 0.33)</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">fT4, pmol/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">16.4 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">16.6 (1.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.09 (&#x02212;0.37 to 0.55)</td><td valign="top" align="center" rowspan="1" colspan="1">0.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (&#x02212;0.39 to 0.52)</td><td valign="top" align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">15.9 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16.1 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">25(OH)D<sub>3</sub>, nmol/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">26 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (19 to 27)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="top" align="center" rowspan="1" colspan="1">23 (18 to 27)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">27 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (12)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Plasma PTH, pmol/L<xref ref-type="table-fn" rid="t2n3"><italic><sup>c</sup></italic></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub></td><td valign="top" align="center" rowspan="1" colspan="1">7.4 (3.6)</td><td valign="top" align="center" rowspan="1" colspan="1">6.0 (2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.54 (&#x02212;2.56 to &#x02212;0.51)</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.50 (&#x02212;2.51 to &#x02212;0.49)</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">8.0 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">8.2 (4.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>The <italic>P</italic> values (TPOAb, TSH, and fT4) were compared with the Benjamini&#x02013;Hochberg critical values. There was no difference in the assessment of statistical significance based on a false discovery rate of 10%.</p></fn><fn id="t2n1"><p><sup><italic>a</italic></sup>Effect (calculated with GEE) with the 250 participants at baseline and 213 at follow-up. Placebo is reference.</p></fn><fn id="t2n2"><p><sup><italic>b</italic></sup>Adjusted for gender, age, and vitamin D at baseline.</p></fn><fn id="t2n3"><p><sup><italic>c</italic></sup>Missing 5 values of PTH at baseline and 3 values at follow-up.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p><bold>Effect of Vitamin D<sub>3</sub> Supplementation (25 &#x000b5;g or 10 &#x000b5;g) on Thyroid Parameters at the End of Intervention Compared With Placebo</bold></p></caption><table frame="above" rules="groups"><col width="23.92" span="1"/><col width="13.65" span="1"/><col width="12.45" span="1"/><col width="20.22" span="1"/><col width="4.77" span="1"/><col width="20.22" span="1"/><col width="4.77" span="1"/><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Baseline<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">After 16 Wk<hr/></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Effect (95% CI) of Vitamin D<sub>3</sub> Compared With Placebo<italic><sup>a</sup></italic><hr/></th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1"><bold><italic>P</italic></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Adjusted Effect (95% CI) of Vitamin D<sub>3</sub> Compared With Placebo<xref ref-type="table-fn" rid="t3n1"><italic><sup>a</sup></italic></xref><sup>,</sup><xref ref-type="table-fn" rid="t3n2"><italic><sup>b</sup></italic></xref><hr/></th><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t3n2"><italic><sup>b</sup></italic></xref></th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Participants, number</td><td valign="top" align="center" rowspan="1" colspan="1">250</td><td valign="top" align="center" rowspan="1" colspan="1">213</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">83</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">85</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">N(%)</td><td valign="top" align="center" rowspan="1" colspan="1">N (%)</td><td valign="top" align="center" rowspan="1" colspan="1">OR</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">OR</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb &#x0003c;100 kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">75 (90%)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (88%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.46 to 1.06)</td><td valign="top" align="center" rowspan="1" colspan="1">0.09</td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.45 to 1.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">78 (92%)</td><td valign="top" align="center" rowspan="1" colspan="1">64 (93%)</td><td valign="top" align="center" rowspan="1" colspan="1">1.05 (0.59 to 1.88)</td><td valign="top" align="center" rowspan="1" colspan="1">0.87</td><td valign="top" align="center" rowspan="1" colspan="1">1.05 (0.58 to 1.88)</td><td valign="top" align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">72 (88%)</td><td valign="top" align="center" rowspan="1" colspan="1">63 (89%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb &#x0003c;50 kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">38 (46%)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (30%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.83 (0.37 to 1.85)</td><td valign="top" align="center" rowspan="1" colspan="1">0.65</td><td valign="top" align="center" rowspan="1" colspan="1">0.82 (0.36 to 1.86)</td><td valign="top" align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">48 (57%)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (39%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.81 (0.35 to 1.85)</td><td valign="top" align="center" rowspan="1" colspan="1">0.61</td><td valign="top" align="center" rowspan="1" colspan="1">0.78 (0.33 to 1.83)</td><td valign="top" align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">41 (50%)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (38%)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">Mean (SD)</td><td valign="top" align="center" rowspan="1" colspan="1">B</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">B</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TPOAb, kU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">131 (300)</td><td valign="top" align="center" rowspan="1" colspan="1">147 (317)</td><td valign="top" align="center" rowspan="1" colspan="1">40 (&#x02212;3 to 82)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td><td valign="top" align="center" rowspan="1" colspan="1">39 (&#x02212;4 to 82)</td><td valign="top" align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">92 (202)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (157)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (&#x02212;39 to 64)</td><td valign="top" align="center" rowspan="1" colspan="1">0.64</td><td valign="top" align="center" rowspan="1" colspan="1">14 (&#x02212;37 to 65)</td><td valign="top" align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">129 (282)</td><td valign="top" align="center" rowspan="1" colspan="1">105 (217)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">TSH, mU/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2.2 (2.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.02 (&#x02212;0.56 to 0.61)</td><td valign="top" align="center" rowspan="1" colspan="1">0.93</td><td valign="top" align="center" rowspan="1" colspan="1">0.02 (&#x02212;0.56 to 0.60)</td><td valign="top" align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;0.64 to 0.14)</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.25 (&#x02212;0.64 to 0.14)</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">2.0 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1">2.3 (2.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">fT4, pmol/L</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 25 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">16.5 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">16.8 (2.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 (&#x02212;0.47 to 0.59)</td><td valign="top" align="center" rowspan="1" colspan="1">0.83</td><td valign="top" align="center" rowspan="1" colspan="1">0.03 (&#x02212;0.50 to 0.56)</td><td valign="top" align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Vitamin D<sub>3</sub> 10 &#x000b5;g</td><td valign="top" align="center" rowspan="1" colspan="1">16.2 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">16.5 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.11 (&#x02212;0.39 to 0.62)</td><td valign="top" align="center" rowspan="1" colspan="1">0.66</td><td valign="top" align="center" rowspan="1" colspan="1">0.09 (&#x02212;0.41 to 0.59)</td><td valign="top" align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x02003;Placebo</td><td valign="top" align="center" rowspan="1" colspan="1">15.9 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">16.1 (1.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>The <italic>P</italic> values (TPOAb, TSH, and fT4) were compared with the Benjamini&#x02013;Hochberg critical values. There was no difference in the assessment of statistical significance using a false discovery rate of 10%.</p></fn><fn id="t3n1"><p><sup><italic>a</italic></sup>Effect (calculated with GEE) with the 250 participants at baseline and 213 at follow-up. Placebo is reference.</p></fn><fn id="t3n2"><p><sup><italic>b</italic></sup>Adjusted for gender, age, and vitamin D at baseline.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s22"><title>E. Additional Analyses</title><p>At baseline we found no correlations between 25(OH)D<sub>3</sub> and the main outcomes: TPOAb (r = &#x02212;0.04, <italic>P</italic> = 0.51), TSH (r = &#x02212;0.02, <italic>P</italic> = 0.79), or fT4 (r = 0.05, <italic>P</italic> = 0.46). TPOAb was positively correlated to TSH (r = 0.33, <italic>P</italic> &#x0003c; 0.001) but not to fT4 (r = 0.03, <italic>P</italic> = 0.62) or CRP (r = 0.01, <italic>P</italic> = 0.93). Albumin at baseline was not correlated to 25(OH)D<sub>3</sub> (r = &#x02212;0.01, <italic>P</italic> = 0.83), TPOAb (r = 0.08, <italic>P</italic> = 0.24), TSH (r = &#x02212;0.01, <italic>P</italic> = 0.84), or fT4 (r = 0.16, <italic>P</italic> = 0.013).</p></sec></sec><sec id="s23"><title>3. Discussion</title><p>The use of 16 weeks of daily vitamin D<sub>3</sub> supplementation (25 &#x000b5;g/d or 10 &#x000b5;g/d) showed no significant effect on thyroid autoimmunity or status compared with placebo in this study among adult, presumed healthy study participants from ethnic minorities living in Norway. The trial had a high prevalence of participants with serum 25(OH)D<sub>3</sub> &#x0003c;50 nmol/L at baseline.</p><sec id="s24"><title>A. Strengths and Weaknesses</title><p>The study followed CONSORT guidelines (<ext-link ext-link-type="uri" xlink:href="http://www.consort-statement.org">http://www.consort-statement.org</ext-link>) for randomized trials and had a high rate of retention to follow-up (86%). The trial was performed during winter and spring, a time with minimal impact of sun exposure on vitamin D synthesis at this latitude (60&#x000b0;N). The vitamin D status of the participants was not known by inclusion. The blood samples from baseline and follow-up were analyzed in a single batch.</p><p>None of the included participants reported use of thyroid hormones, and their TPOAb level was unknown by inclusion. Thus participants in an early stage of an AITD, subclinical hypothyroidism, could have been included. Association studies indicate that vitamin D supplementation can reduce the risk for development and progression of autoimmune diseases [<xref rid="B7" ref-type="bibr">7</xref>]. However, a 16-week supplementation period could have been too short to see any effect in an early stage of an AITD, measured by changes in TPOAb or TSH. More women than men were recruited, rendering gender comparisons less efficient, but women have a higher prevalence of AITD than men. Although 16 weeks of supplementation with vitamin D raised the serum levels in the intervention groups, not all participants attained a serum level of 25(OH)D<sub>3</sub> &#x02265;50 nmol/L at the end of the trial [<xref rid="B21" ref-type="bibr">21</xref>]. However, an association with change in 25(OH)D<sub>3</sub> and change in TPOAb, independent of randomization group, was not found. The TPOAb showed a wide range of levels, and the effect of the intervention on TPOAb had a broad 95% CI. A sensitivity analysis of only participants with TPOAb &#x0003c;100 kU/L at baseline (90%) gave a narrow CI but still no effect of intervention. Power calculations to determine the sample size of the study were based on expected changes in muscle strength (results reported elsewhere) and not affected by thyroid function parameters [<xref rid="B21" ref-type="bibr">21</xref>].</p></sec><sec id="s25"><title>B. Comparison With Other Studies</title><sec id="s26"><title>B-1. Baseline characteristics and associations</title><p>Effraimidis <italic>et al.</italic> found no association between low vitamin D levels and early stage of thyroid autoimmunity in their cross-sectional part (study A) of a case&#x02013;control study among euthyroid subjects with genetic susceptibility for AITD [<xref rid="B19" ref-type="bibr">19</xref>]. Wang <italic>et al.</italic> conducted a meta-analysis from published studies up to December 2014 of the association between vitamin D and AITD. They found a higher prevalence of vitamin D deficiency (OR 2.99; 95% CI, 1.88 to 4.74) and lower vitamin D levels in patients with AITD compared with controls [<xref rid="B6" ref-type="bibr">6</xref>]. Many of these observational studies did not adjust for confounders and concluded that additional randomized controlled trials were needed to clarify whether reduced vitamin D level is a causal factor in the pathogenesis of AITD or a consequence [<xref rid="B6" ref-type="bibr">6</xref>]. Our participants, with a high percentage (92%) of vitamin D deficiency (serum 25(OH)D<sub>3</sub> &#x0003c;50 nmol/L) and TPOAb within a wide range, showed no significant baseline correlation between 25(OH)D<sub>3</sub> and TPOAb or TSH.</p></sec><sec id="s27"><title>B-2. Effect of vitamin D-supplementation</title><p>Few studies have investigated the effect of vitamin D supplementation on thyroid autoimmunity. Effraimidis <italic>et al.</italic> found that development of TPOAb was not associated with low vitamin D levels in their longitudinal (study B) case&#x02013;control study [<xref rid="B19" ref-type="bibr">19</xref>]. Krysiak <italic>et al.</italic> found an effect of vitamin D supplementation on thyroid autoimmunity in nonlactating women with postpartum thyroiditis compared with matched healthy postpartum women, in an open, not randomized study [<xref rid="B23" ref-type="bibr">23</xref>]. But postpartum, it cannot be excluded that thyroid autoantibodies spontaneously decreased with time and even sometimes return to euthyroid state within 12 months [<xref rid="B24" ref-type="bibr">24</xref>]. D&#x02019;Aurizio <italic>et al.</italic> found in their review that genetic studies demonstrated an association between AITD and gene polymorphism of vitamin D receptor, vitamin D binding protein, and 1-<italic>&#x003b1;</italic>-hydroxylase and 25-hydroxylase but that the role of vitamin D in AITD remains controversial [<xref rid="B25" ref-type="bibr">25</xref>]. They concluded that more randomized, controlled, prospective trials are needed to demonstrate the causality of vitamin D in AITD and consequently the role of vitamin D supplementation in prevention or improvement of AITD. Chaudhary <italic>et al.</italic> found a reduction in TPOAb titers among patients with AITD treated with cholecalciferol 60,000 IU/wk for 8 weeks compared with the control group (<italic>P</italic> = 0.028) in an open-label, randomized controlled trial [<xref rid="B18" ref-type="bibr">18</xref>]. In our double-blinded, randomized controlled trial we found that the percentage of participants with low titers of TPOAb (&#x0003c;50 kU/L) decreased after 16 weeks, but there was no difference in the effects of vitamin D supplementation compared with placebo on TPOAb, TSH, or fT4. Links between inflammation and vitamin D and between inflammation and AITD have been found in other studies. Chandler <italic>et al.</italic> found no effect on CRP in healthy African Americans after 3 months of vitamin D supplementation, although the participants with 25(OH)D &#x0003c;50 nmol/L at baseline had higher CRP levels [<xref rid="B26" ref-type="bibr">26</xref>]. We focused on CRP as a possible marker of inflammation in thyroid autoimmunity. However, in our presumed healthy population of immigrants with low levels of 25(OH)D<sub>3</sub>, we found no correlation between CRP and TPOAb or CRP and 25(OH)D levels at baseline, and as previously reported supplementation with vitamin D did not decrease levels of CRP [<xref rid="B22" ref-type="bibr">22</xref>]. Patients with diagnosed AITD and high levels of inflammatory markers may react differently to vitamin D supplementation than our presumed healthy participants. Not all participants in the supplement groups might have been exposed to sufficient 25(OH)D<sub>3</sub> levels within a sufficient period of time to affect thyroid status. On the other hand, a study period &#x0003e;16 weeks might have contributed to a greater loss to follow-up and to some impact of the sun (vitamin D&#x02013;producing UV B rays), and thus blurring the differences between the groups. A higher vitamin D supplementation dosage might have exposed the thyroid autoimmune regulatory system to a higher 25(OH)D level, even though we found no effect of 25-&#x000b5;g vitamin D supplementation on thyroid status compared with placebo. However, we cannot extrapolate our findings to patients with a diagnosis and symptoms of AITD.</p></sec></sec><sec id="s28"><title>C. Conclusion</title><p>Daily supplementation of vitamin D<sub>3</sub> (25 &#x000b5;g or 10 &#x000b5;g) for 16 weeks compared with placebo had no effect on TPOAb, fT4, or TSH among a population of adult immigrants from the Middle East, Africa, or South Asia living in Norway.</p></sec></sec></body><back><fn-group content-type="abbreviations"><fn id="abbr" fn-type="abbr"><p>Abbreviations: <def-list><def-item><term id="G1">25(OH)D</term><def><p>25-hydroxyvitamin D</p></def></def-item><def-item><term id="G2">AITD</term><def><p>autoimmune thyroid disease</p></def></def-item><def-item><term id="G3">CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term id="G4">CV</term><def><p>coefficient of variation</p></def></def-item><def-item><term id="G5">fT4</term><def><p>free fraction of thyroxine</p></def></def-item><def-item><term id="G6">GEE</term><def><p>generalized estimating equation</p></def></def-item><def-item><term id="G7">IQR</term><def><p>interquartile range</p></def></def-item><def-item><term id="G8">OR</term><def><p>odds ratio</p></def></def-item><def-item><term id="G9">PTH</term><def><p>parathyroid hormone</p></def></def-item><def-item><term id="G10">TPOAb</term><def><p>antithyroid peroxidase antibody</p></def></def-item><def-item><term id="G11">TSH</term><def><p>thyroid-stimulating hormone.</p></def></def-item></def-list></p></fn></fn-group><ack><title>Acknowledgments</title><p>The authors thank Eva Kristensen and Morten Ariansen for their help with data collection, Anne Karen Jenum for the biobank support, and Marie Buchmann and Anne-Lise Sund at F&#x000fc;rst Medical Laboratory for facilitating the laboratory analyses. Finally, we extend our gratitude to the study participants who participated in this 16-week trial and the organizations that allowed us to use their venues for recruitment and data collection.</p></ack><ack><p content-type="financial-disclosure">The study was sponsored by the Institute of Health and Society, University of Oslo, Norway. The study was also supported by the Norwegian Women&#x02019;s Public Health Association, F&#x000fc;rst Medical Laboratory, and Nycomed Pharma AS, including free trial drugs. None of the supporting bodies had any influence on the performance of the trial, data analyses, writing, or publication of the results.</p><p>Clinical Trial Registry: ClinicalTrials.gov no. NCT01263288.</p><p>Disclosure Summary: The authors have nothing to disclose.</p></ack><ref-list><title>References and Notes</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taksler</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Cutler</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Giovannucci</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Keating</surname><given-names>NL</given-names></name></person-group>
<article-title>Vitamin D deficiency in minority populations</article-title>. <source>Public Health Nutr</source>. <year>2015</year>;<volume>18</volume>(<issue>3</issue>):<fpage>379</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">25112179</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prentice</surname><given-names>A</given-names></name></person-group>
<article-title>Vitamin D deficiency: a global perspective</article-title>. <source>Nutr Rev</source>. <year>2008</year>;<volume>66</volume>(<issue>10</issue>, <supplement>suppl 2</supplement>)<fpage>S153</fpage>&#x02013;<lpage>S164</lpage>.<pub-id pub-id-type="pmid">18844843</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cashman</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Dowling</surname><given-names>KG</given-names></name>, <name name-style="western"><surname>&#x00160;krab&#x000e1;kov&#x000e1;</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Gonzalez-Gross</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Valtue&#x000f1;a</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Henauw</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Moreno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Damsgaard</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Michaelsen</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>M&#x000f8;lgaard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jorde</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Grimnes</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Moschonis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mavrogianni</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Manios</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Thamm</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mensink</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Rabenberg</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Busch</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Meadows</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goldberg</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Prentice</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dekker</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Nijpels</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pilz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Swart</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>van Schoor</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Lips</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Eiriksdottir</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gudnason</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cotch</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Koskinen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lamberg-Allardt</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Durazo-Arvizu</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Sempos</surname><given-names>CT</given-names></name>, <name name-style="western"><surname>Kiely</surname><given-names>M</given-names></name></person-group>
<article-title>Vitamin D deficiency in Europe: pandemic?</article-title>
<source>Am J Clin Nutr</source>. <year>2016</year>;<volume>103</volume>(<issue>4</issue>):<fpage>1033</fpage>&#x02013;<lpage>1044</lpage>.<pub-id pub-id-type="pmid">26864360</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holvik</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Haug</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brunvand</surname><given-names>L</given-names></name></person-group>
<article-title>Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, Norway: the Oslo Immigrant Health Study</article-title>. <source>Eur J Clin Nutr</source>. <year>2005</year>;<volume>59</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">15280907</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eggemoen</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Knutsen</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Dalen</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jenum</surname><given-names>AK</given-names></name></person-group>
<article-title>Vitamin D status in recently arrived immigrants from Africa and Asia: a cross-sectional study from Norway of children, adolescents and adults</article-title>. <source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>(<issue>10</issue>):<fpage>e003293</fpage>.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>C</given-names></name>, <name name-style="western"><surname>He</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name></person-group>
<article-title>Meta-analysis of the association between vitamin D and autoimmune thyroid disease</article-title>. <source>Nutrients</source>. <year>2015</year>;<volume>7</volume>(<issue>4</issue>):<fpage>2485</fpage>&#x02013;<lpage>2498</lpage>.<pub-id pub-id-type="pmid">25854833</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prietl</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Treiber</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pieber</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Amrein</surname><given-names>K</given-names></name></person-group>
<article-title>Vitamin D and immune function</article-title>. <source>Nutrients</source>. <year>2013</year>;<volume>5</volume>(<issue>7</issue>):<fpage>2502</fpage>&#x02013;<lpage>2521</lpage>.<pub-id pub-id-type="pmid">23857223</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holick</surname><given-names>MF</given-names></name></person-group>
<article-title>Vitamin D deficiency</article-title>. <source>N Engl J Med</source>. <year>2007</year>;<volume>357</volume>(<issue>3</issue>):<fpage>266</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">17634462</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cantorna</surname><given-names>MT</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bruce</surname><given-names>D</given-names></name></person-group>
<article-title>The paradoxical effects of vitamin D on type 1 mediated immunity</article-title>. <source>Mol Aspects Med</source>. <year>2008</year>;<volume>29</volume>(<issue>6</issue>):<fpage>369</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">18561994</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnson</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Amital</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>
<article-title>Vitamin D and autoimmunity: new aetiological and therapeutic considerations</article-title>. <source>Ann Rheum Dis</source>. <year>2007</year>;<volume>66</volume>(<issue>9</issue>):<fpage>1137</fpage>&#x02013;<lpage>1142</lpage>.<pub-id pub-id-type="pmid">17557889</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hollowell</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Staehling</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Flanders</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Hannon</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Gunter</surname><given-names>EW</given-names></name>, <name name-style="western"><surname>Spencer</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Braverman</surname><given-names>LE</given-names></name></person-group>
<article-title>Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2002</year>;<volume>87</volume>(<issue>2</issue>):<fpage>489</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">11836274</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prummel</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Strieder</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wiersinga</surname><given-names>WM</given-names></name></person-group>
<article-title>The environment and autoimmune thyroid diseases</article-title>. <source>Eur J Endocrinol</source>. <year>2004</year>;<volume>150</volume>(<issue>5</issue>):<fpage>605</fpage>&#x02013;<lpage>618</lpage>.<pub-id pub-id-type="pmid">15132715</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medici</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Porcu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Pistis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Teumer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Rawal</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Roef</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Plantinga</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Vermeulen</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Lahti</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Simmonds</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Husemoen</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Freathy</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Shields</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Pietzner</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nagy</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Broer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chaker</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Korevaar</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Plia</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Sala</surname><given-names>C</given-names></name>, <name name-style="western"><surname>V&#x000f6;lker</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Sweep</surname><given-names>FC</given-names></name>, <name name-style="western"><surname>Gieger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Corre</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kajantie</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Thuesen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Taes</surname><given-names>YE</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Hattersley</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Kratzsch</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Homuth</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lobina</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mariotti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Soranzo</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Cocca</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nauck</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Spielhagen</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arnold</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van de Bunt</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liyanarachchi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Heier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grabe</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Masciullo</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Galesloot</surname><given-names>TE</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Reischl</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Leedman</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Delitala</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bremner</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Philips</surname><given-names>DI</given-names></name>, <name name-style="western"><surname>Beilby</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Mulas</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vocale</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Abecasis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Forsen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>James</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Widen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hui</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Prokisch</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Rietzschel</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Palotie</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Feddema</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Fletcher</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Schramm</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rotter</surname><given-names>JI</given-names></name>, <name name-style="western"><surname>Kluttig</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Radke</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Traglia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Surdulescu</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>He</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Franklyn</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Tiller</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Vaidya</surname><given-names>B</given-names></name>, <name name-style="western"><surname>de Meyer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>J&#x000f8;rgensen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Eriksson</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>O&#x02019;Leary</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Wichmann</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hermus</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Psaty</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Ittermann</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bosi</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schlessinger</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wallaschofski</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pirastu</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Aulchenko</surname><given-names>YS</given-names></name>, <name name-style="western"><surname>de la Chapelle</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Netea-Maier</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Gough</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Meyer Zu Schwabedissen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Frayling</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Kaufman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Linneberg</surname><given-names>A</given-names></name>, <name name-style="western"><surname>R&#x000e4;ikk&#x000f6;nen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Smit</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Kiemeney</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Rivadeneira</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Uitterlinden</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Walsh</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Meisinger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>den Heijer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Visser</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Spector</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>V&#x000f6;lzke</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Cappola</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Toniolo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sanna</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Naitza</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Peeters</surname><given-names>RP</given-names></name></person-group>
<article-title>Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease</article-title>. <source>PLoS Genet</source>. <year>2014</year>;<volume>10</volume>(<issue>2</issue>):<fpage>e1004123</fpage>.<pub-id pub-id-type="pmid">24586183</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schultheiss</surname><given-names>UT</given-names></name>, <name name-style="western"><surname>Teumer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Medici</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Daya</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chaker</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Homuth</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Uitterlinden</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Nauck</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hofman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Selvin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>V&#x000f6;lzke</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Peeters</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name></person-group>
<article-title>A genetic risk score for thyroid peroxidase antibodies associates with clinical thyroid disease in community-based populations</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2015</year>;<volume>100</volume>(<issue>5</issue>):<fpage>E799</fpage>&#x02013;<lpage>E807</lpage>.<pub-id pub-id-type="pmid">25719932</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baumgartner</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Blum</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Rodondi</surname><given-names>N</given-names></name></person-group>
<article-title>Subclinical hypothyroidism: summary of evidence in 2014</article-title>. <source>Swiss Med Wkly</source>. <year>2014</year>;<volume>144</volume>:<fpage>w14058</fpage>.<pub-id pub-id-type="pmid">25536449</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kivity</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Agmon-Levin</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Zisappl</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Shapira</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nagy</surname><given-names>EV</given-names></name>, <name name-style="western"><surname>Dank&#x000f3;</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Szekanecz</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Langevitz</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>
<article-title>Vitamin D and autoimmune thyroid diseases</article-title>. <source>Cell Mol Immunol</source>. <year>2011</year>;<volume>8</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">21278761</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simsek</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cak&#x00131;r</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Yetmis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dizdar</surname><given-names>OS</given-names></name>, <name name-style="western"><surname>Baspinar</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Gokay</surname><given-names>F</given-names></name></person-group>
<article-title>Effects of vitamin D treatment on thyroid autoimmunity</article-title>. <source>J Res Med Sci</source>. <year>2016</year>;<volume>21</volume>:<fpage>85</fpage>.<pub-id pub-id-type="pmid">28163731</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaudhary</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dutta</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Saha</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mondal</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mukhopadhyay</surname><given-names>S</given-names></name></person-group>
<article-title>Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: an open-labeled randomized controlled trial</article-title>. <source>Indian J Endocrinol Metab</source>. <year>2016</year>;<volume>20</volume>(<issue>3</issue>):<fpage>391</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">27186560</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Effraimidis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Badenhoop</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tijssen</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Wiersinga</surname><given-names>WM</given-names></name></person-group>
<article-title>Vitamin D deficiency is not associated with early stages of thyroid autoimmunity</article-title>. <source>Eur J Endocrinol</source>. <year>2012</year>;<volume>167</volume>(<issue>1</issue>):<fpage>43</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">22518050</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kmie&#x00107;</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sworczak</surname><given-names>K</given-names></name></person-group>
<article-title>Vitamin D in thyroid disorders</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2015</year>;<volume>123</volume>(<issue>7</issue>):<fpage>386</fpage>&#x02013;<lpage>393</lpage>.<pub-id pub-id-type="pmid">26171622</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knutsen</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Madar</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Lagerl&#x000f8;v</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Brekke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Raastad</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Stene</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>HE</given-names></name></person-group>
<article-title>Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2014</year>;<volume>99</volume>(<issue>1</issue>):<fpage>194</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">24248184</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knutsen</surname><given-names>KV</given-names></name>, <name name-style="western"><surname>Madar</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Brekke</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Natvig</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mdala</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Lagerl&#x000f8;v</surname><given-names>P</given-names></name></person-group>
<article-title>Effect of vitamin D on musculoskeletal pain and headache: a randomized, double-blind, placebo-controlled trial among adult ethnic minorities in Norway</article-title>. <source>Pain</source>. <year>2014</year>;<volume>155</volume>(<issue>12</issue>):<fpage>2591</fpage>&#x02013;<lpage>2598</lpage>.<pub-id pub-id-type="pmid">25261164</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krysiak</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kowalcze</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Okopien</surname><given-names>B</given-names></name></person-group>
<article-title>The effect of vitamin D on thyroid autoimmunity in non-lactating women with postpartum thyroiditis</article-title>. <source>Eur J Clin Nutr</source>. <year>2016</year>;<volume>70</volume>(<issue>5</issue>):<fpage>637</fpage>&#x02013;<lpage>639</lpage>.<pub-id pub-id-type="pmid">26757834</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Corapcioglu</surname><given-names>D</given-names></name></person-group>
<article-title>The effect of vitamin D on thyroid autoimmunity in non-lactating women with postpartum thyroiditis</article-title>. <source>Eur J Clin Nutr</source>. <year>2016</year>;<volume>70</volume>(<issue>7</issue>):<fpage>864</fpage>.<pub-id pub-id-type="pmid">27049036</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#x02019;Aurizio</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Villalta</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Metus</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Doretto</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tozzoli</surname><given-names>R</given-names></name></person-group>
<article-title>Is vitamin D a player or not in the pathophysiology of autoimmune thyroid diseases?</article-title>
<source>Autoimmun Rev</source>. <year>2015</year>;<volume>14</volume>(<issue>5</issue>):<fpage>363</fpage>&#x02013;<lpage>369</lpage>.<pub-id pub-id-type="pmid">25308530</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandler</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Scott</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Drake</surname><given-names>BF</given-names></name>, <name name-style="western"><surname>Ng</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Manson</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Rifai</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Hollis</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Giovannucci</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Emmons</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>CS</given-names></name></person-group>
<article-title>Impact of vitamin D supplementation on inflammatory markers in African-Americans: results of a four-arm, randomized, placebo-controlled trial</article-title>. <source>Cancer Prev Res (Phila)</source>. <year>2014</year>;<volume>7</volume>(<issue>2</issue>):<fpage>218</fpage>&#x02013;<fpage>225</fpage>.<pub-id pub-id-type="pmid">24327720</pub-id></mixed-citation></ref></ref-list></back></article>